

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
1	18/LO/1238	245332	Open Label Extension study of WVE-210201 in patients with DMD	04/10/2018	14/01/2019	25/10/2018	01/02/2019	19/02/2019	07/03/2019	08/05/2019	Neither
2	18/EE/0373	249396	Breast Cancer Her 2	15/05/2018	17/01/2019	19/01/2019	22/02/2019	25/02/2019	08/03/2019	16/05/2019	Neither
3	18/LO/1450	248611	Marigold Study 4407/0001 Marinus	18/10/2018	21/01/2019	07/12/2018	29/01/2019	29/01/2019	06/02/2019	14/05/2019	Neither
4	18/NW/0812	254035	CAIN457M2301 (SUNSHINE): Secukinumab in hidradenitis suppurativa	02/11/2018	21/01/2019	16/01/2019	31/01/2019	04/02/2019	22/02/2019	22/10/2019	Neither
5	18/SC/0243	240684	ORION-4	25/07/2018	04/02/2019	17/10/2018	22/02/2019	28/02/2019	01/05/2019	15/05/2019	Sponsor
6	18/SC/0016	191852	Focus: A study to test a new treatment for dry AMD	19/02/2018	11/02/2019	23/04/2018	10/01/2019	15/02/2019	18/02/2019	29/05/2019	Neither
7	19/YH/0013	255993	Phase 3 - XL184 in Combination with Atezolizumab vs Sorafenib in HCC	11/12/2018	12/08/2019	15/02/2019	18/07/2019	12/08/2019	20/08/2019	16/12/2019	Neither
8	19/EM/0003	251874	Phase 3 Study of Edasalonexent in Duchenne Muscular Dystrophy	21/12/2018	27/02/2019	20/02/2019	21/03/2019	22/03/2019	22/03/2019	30/04/2019	Benchmark Met
9	18/NE/0312	245315	LTE Efficacy / Safety Study Of PF-04965842, w/wo T'cal Meds, in Subjs 12+ years with Mod to Sev AD	27/11/2018	19/03/2019	16/11/2018	15/02/2019	22/03/2019	19/06/2019	20/06/2019	Neither
10	18/NW/0699	241427	TACE-3	14/01/2019	05/09/2019	21/03/2019	23/10/2019	25/10/2019			Sponsor
11	18/EE/0378	248600	Conbercept in Neovascular Age-related Macular Degeneration	20/11/2018	21/03/2019	10/01/2019	27/03/2019	28/03/2019	18/04/2019	17/05/2019	Benchmark Met
12	18/NE/0264	250542	TRACKER	05/02/2019	25/03/2019	27/09/2018	26/03/2019	27/03/2019	28/03/2019		Sponsor
13	18/EE/0099	239606	CL3-95005-006 SOLSTICE	08/02/2019	01/05/2019	01/06/2018	01/05/2019	03/05/2019	30/05/2019	13/06/2019	Benchmark Met
14	19/SC/0113	241916	Idera 2125-MEL-301	20/07/2017	30/05/2019	24/04/2019	19/06/2019	19/06/2019	19/06/2019	20/06/2019	Benchmark Met
15	18/WM/0324	246654	FORCE - Forearm fracture Recovery in Children Evaluation	11/10/2018	14/01/2019	16/11/2018	14/01/2019	04/02/2019	13/02/2019	14/02/2019	Benchmark Met
16	18/SC/0471	242624	Service-review and Feasibility Trial in Paediatric Weight Management	11/01/2019	21/01/2019	08/11/2018	04/02/2019	04/02/2019	03/07/2019	10/07/2019	Sponsor
17	18/WS/0172	251636	1011712	25/09/2018	31/01/2019	03/01/2019	06/02/2019	08/02/2019	27/05/2019		Sponsor
18	18/SC/0222	223737	NeoCLEAR	29/11/2018	06/02/2019	12/06/2018	06/02/2019	09/05/2019	09/05/2019	23/05/2019	Sponsor
19	17/LO/1622	219932	Inotuzumab Ozogamicin for treatment of pediatric BCP-ALL	23/03/2017	13/02/2019	12/02/2018	13/02/2019	10/05/2019	13/05/2019		Neither
20	18/SS/0010	238051	Erdafitinib compared with Vinflunine or Docetaxel or Pembrolizumab	06/03/2018	04/04/2019	21/03/2018	27/03/2019	09/04/2019	10/04/2019	14/06/2019	Neither
21	18/LO/0745	231612	IL-1 Signal Inhibition in Alcoholic Hepatitis (Isaiah)	21/11/2018	08/04/2019	11/07/2018	03/05/2019	09/05/2019	16/05/2019		Neither
22	18/SC/0242	238151	BLING III study	25/06/2018	09/04/2019	24/08/2018	16/04/2019	18/06/2019	24/06/2019	25/06/2019	Sponsor
23	19/EM/0047	257111	GR40306 (TENAYA): A study of faricimab in nAMD	05/11/2018	10/04/2019	04/04/2019	08/04/2019	15/04/2019	30/04/2019	05/06/2019	Benchmark Met
24	19/NI/0032	242580	3185/0004_Follicular Lymphoma Nordic Nanovector AS	14/01/2019	17/04/2019	01/04/2019	25/04/2019	21/05/2019	16/08/2019		Neither
25	18/WA/0420	246637	Spironolactone for Adult Female Acne	21/01/2019	26/04/2019	04/02/2019	03/06/2019	11/06/2019	24/06/2019	23/07/2019	Sponsor

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
26	18/LO/1187	240011	ATHENA - a first line ovarian cancer maintenance trial.	31/07/2018	13/05/2019	11/09/2018	19/06/2019	24/06/2019	27/06/2019	16/09/2019	Neither
27	17/YH/0187	218853	PRISM Trial	17/07/2018	24/05/2019	11/10/2017	24/05/2019	17/06/2019	05/07/2019	04/10/2019	Neither
28	18/SW/0045	239151	Mistletoe And Breast Cancer (MAB)	11/06/2018	05/06/2019	02/04/2019	05/06/2019	20/06/2019	30/07/2019	13/09/2019	Neither
29	19/LO/1024	263894	Pembrolizumab ± SBRT in Medically Inoperable Stage I/IIA NSCLC	05/06/2019	05/06/2019	26/07/2019	06/08/2019	16/08/2019	23/08/2019	03/10/2019	Neither
30	18/SS/0085	243640	Alpha-2 agonists for sedation (A2B Trial)	31/05/2019	02/08/2019	14/12/2018	09/08/2019	20/08/2019	12/12/2019		Sponsor
31	17/LO/1875	219487	Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)	03/07/2018	12/06/2019	08/01/2018	12/07/2019	19/07/2019	24/07/2019	18/10/2019	Neither
32	19/YH/0079	259791	Cabozantinib in Radioiodine-Refractory Differentiated Thyroid Cancer	11/03/2019	19/08/2019	09/05/2019	31/07/2019	19/08/2019	30/08/2019		Neither
33	19/NW/0106	257112	Long-Term safety and efficacy of baricitinib - 14V-MC-JAHV	22/01/2019	14/06/2019	10/06/2019	04/06/2019	14/06/2019	24/06/2019	05/07/2019	Benchmark Met
34	19/EM/0063	253607	AMADEUS	11/03/2019	26/06/2019	14/05/2019	26/06/2019	30/08/2019	02/09/2019	18/09/2019	Both
35	18/LO/0555	237992	PROTECTOR	07/08/2018	25/03/2019	19/04/2018	13/05/2019	13/05/2019	24/06/2019	07/08/2019	Sponsor
36	17/EE/0213	201374	Image guided radiotherapy and adaptive brachytherapy for cervix cancer	11/01/2019	05/04/2019	09/10/2017	05/04/2019	05/08/2019	28/10/2019		Sponsor
37	18/YH/0358	242342	The Sunflower Study	02/10/2018	09/04/2019	12/12/2018	09/04/2019	10/04/2019	10/04/2019	15/04/2019	Benchmark Met
38	18/YH/0236	230191	PROTHOR	13/03/2019	10/04/2019	17/10/2018	10/04/2019	23/04/2019	24/04/2019	20/05/2019	Benchmark Met
39	17/WA/0192	227541	TAME Cardiac Arrest Trial	13/09/2018	11/04/2019	13/06/2018	15/05/2019	17/05/2019	20/05/2019	20/05/2019	Benchmark Met
40	17/SW/0250	222991	Conventional versus minimally invasive extra-corporeal circulation	26/02/2019	29/04/2019	29/11/2017	22/04/2019	17/05/2019	28/05/2019	02/06/2019	Benchmark Met
41	18/WA/0337	248818	TIME: Take home naloxone Intervention Multi centre Emergency setting feasibility trial	17/01/2019	16/05/2019	08/01/2019	16/05/2019	04/06/2019	04/06/2019	04/06/2019	Benchmark Met
42	19/YH/0050	249236	OpTIMUM	08/04/2019	28/05/2019	28/03/2019	28/05/2019	03/06/2019	03/06/2019	26/06/2019	Benchmark Met
43	19/NW/0158	259931	Surgery or Cast for Injuries of the Epicondyle in Children's Elbows	05/06/2019	05/06/2019	25/03/2019	25/07/2019	30/07/2019	14/08/2019	17/09/2019	Both
44	18/LO/2111	254025	The FENETRE Study	06/06/2019	07/06/2019	25/03/2019	21/06/2019	21/06/2019	17/10/2019	12/11/2019	Sponsor
45	17/LO/1334	217338	TOXYC: Targeted OXYgen therapy in Critical illness	16/05/2019	25/06/2019	13/11/2017					Benchmark Met
46	19/NW/0174	261666	Biliary Tract Cancer - Durva (TOPAZ-1)	19/03/2019	24/06/2019	28/05/2019	26/07/2019	25/10/2019	12/11/2019	03/12/2019	NHS Provider
47	17/SC/0476	186573	MERIT	25/07/2018	11/07/2019	07/11/2017	25/07/2019	30/07/2019	18/10/2019	04/12/2019	Both
48	19/EE/0105	259619	JUVE-X/ Long term safety and efficacy of baricitinib	10/04/2019	12/07/2019	24/06/2019	28/08/2019	29/08/2019	02/12/2019		Neither
49	18/SC/0342	247085	Phase III Trial of AMT-061 in adults with haemophilia B	14/05/2019	15/07/2019	06/09/2018	09/07/2019	18/07/2019	30/07/2019		Sponsor
50	19/SW/0039	253195	GLOW	30/08/2018	16/07/2019	20/05/2019	30/10/2019	01/11/2019	15/11/2019	30/12/2019	NHS Provider
51	19/EE/0185	260536	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC)	03/06/2019	19/07/2019	26/07/2019	05/09/2019	09/09/2019	07/10/2019	14/10/2019	Sponsor

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
52	19/LO/0714	246398	Red cell transfusion in Paediatric Allogeneic HSCT (RePAST)	07/05/2019	24/07/2019	24/06/2019	30/08/2019	03/09/2019	03/09/2019	18/09/2019	Benchmark Met
53	19/YH/0067	254066	CANOPY-1	23/03/2019	26/07/2019	23/04/2019	07/08/2019	14/08/2019	19/08/2019		Sponsor
54	19/LO/0952	262142	Phase 3 Study of Pembrolizumab plus Docetaxel in mCRPC	08/02/2019	26/07/2019	14/08/2019	05/08/2019	06/08/2019	28/08/2019		Neither
55	19/SC/0253	264426	Open label study of BI 754132 in patients with Geographic Atrophy.	23/05/2019	31/07/2019	08/07/2019	02/08/2019	02/08/2019	20/08/2019	02/10/2019	Benchmark Met
56	18/NE/0282	248188	20170534: Extension of Study 20130173 in Children and Young Adults with OI	22/08/2018	05/08/2019	13/03/2019	16/08/2019	16/08/2019	20/08/2019	09/10/2019	Benchmark Met
57	19/SC/0086	249778	A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors	19/10/2018	05/08/2019	06/06/2019	02/10/2019	07/11/2019	07/11/2019		Sponsor
58	19/NI/0110	260538	EluNIR HBR study	25/03/2019	05/08/2019	19/07/2019	04/08/2019	19/08/2019	25/08/2019	20/09/2019	Benchmark Met
59	19/EM/0020	252705	TAPER	03/07/2019	21/08/2019	23/05/2019	22/08/2019	27/08/2019	11/10/2019		Sponsor
60	19/NW/0442	262204	JUVE BRIGHT	18/06/2019	28/08/2019	06/08/2019	29/08/2019	02/09/2019	18/09/2019	31/10/2019	Benchmark Met
61	19/YH/0158	262107	TRANSITION	13/06/2019	28/08/2019	26/07/2019	04/09/2019	12/09/2019	03/10/2019	12/11/2019	Sponsor
62	19/LO/1057	261202	Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC	08/02/2019	30/08/2019	28/08/2019	02/09/2019	12/09/2019	12/09/2019	29/10/2019	Benchmark Met
63	18/NW/0694	248847	Derby - Geographic Atrophy secondary to AMD	06/08/2018	30/08/2019	07/12/2018	02/09/2019	02/09/2019	13/11/2019		Sponsor
64	19/YH/0247	266732	4451-STEP TEENS-semaglutide effect in adolescents with obesity	24/07/2019	27/09/2019	25/09/2019	30/10/2019	06/11/2019	12/11/2019		Neither
65	16/SC/0651	213404	High Energy High Protein Peptide Feed Study	01/08/2019	06/09/2019	13/01/2017	12/09/2019	13/09/2019	03/10/2019	12/11/2019	Benchmark Met
66	17/LO/1476	224732	A phase 2a Study in Adult Volunteers with Sickle Cell Anaemia - 001	20/06/2019	09/09/2019	19/10/2017	04/09/2019	10/09/2019	12/09/2019	16/10/2019	Benchmark Met
67	19/NW/0443	264683	JAHU; Oral baricitinib in patients 1-18 years with systemic JIA	25/06/2019	11/09/2019	19/08/2019	14/10/2019	14/10/2019	06/11/2019		Neither
68	19/LO/0928	262406	Pembrolizumab+Olaparib vs Abiraterone Acetate or Enzalutamide in mCRPC	31/05/2019	12/09/2019	10/09/2019	10/10/2019	16/10/2019	17/10/2019		Neither
69	17/LO/0980	219505	HALT - Stereotactic Body Radiotherapy for the treatment of OPD	02/09/2019	19/09/2019	10/07/2017	02/12/2019	02/12/2019	03/12/2019		NHS Provider
70	19/NW/0482	269475	Kepler	18/06/2019	20/09/2019	27/09/2019	09/10/2019	14/10/2019	17/10/2019	05/11/2019	Benchmark Met
71	19/EM/0151	259687	Cerebral Palsy-0075/0140-Teva	19/02/2019	23/09/2019	16/07/2019	14/10/2019	18/10/2019	25/10/2019		Neither
72	19/YH/0099	257815	LAT8881 in Neuropathic Pain	30/11/2018	26/09/2019	05/09/2019	26/09/2019	01/10/2019	19/11/2019	12/12/2019	Sponsor
73	18/SC/0427	220853	The Bronchiolitis Endotracheal Surfactant Study (BESS)	21/06/2019	30/09/2019	15/10/2018	30/09/2019	01/10/2019	10/10/2019	20/11/2019	Benchmark Met
74	19/SC/0415	269249	MELODY	20/08/2019	04/10/2019	04/10/2019	17/10/2019	18/10/2019	06/11/2019		Neither
75	19/SC/0416	269256	MEDLEY	20/08/2019	04/10/2019	04/10/2019	17/10/2019	18/10/2019	29/10/2019		Neither
76	19/LO/1367	266879	Cancer-0456/0232-Regeneron	04/06/2019	04/10/2019	04/10/2019	16/12/2019	19/12/2019	24/12/2019		Both

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
77	19/YH/0301	268446	A Phase 2 study of ABBV-3067 alone and in combination with ABBV-2222	05/07/2019	27/11/2019	31/10/2019					70 days not yet reached
78	19/SC/0112	259372	ADJUST	09/05/2019	16/12/2019	12/11/2019	18/12/2019	18/12/2019			70 days not yet reached
79	19/NE/0215	234453	Myeloma XIV (FiTNEss)	23/08/2019	17/12/2019	07/11/2019					70 days not yet reached
80	19/SC/0402	269452	Active comparator-controlled study of KSI-301 in patients with Wet AMD	15/08/2019	20/12/2019	04/11/2019					70 days not yet reached